132 related articles for article (PubMed ID: 27407049)
1. Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study.
Schneeweiss S; Carver PL; Datta K; Galar A; Johnson MD; Johnson MG; Marty FM; Nagel J; Najdzinowicz M; Saul M; Shoham S; Silveira FP; Varughese CA; Wilck M; Weatherby L; Auton T; Walker AM
J Antimicrob Chemother; 2016 Oct; 71(10):2938-44. PubMed ID: 27407049
[TBL] [Abstract][Full Text] [Related]
2. Long-term risk of hepatocellular carcinoma mortality in 23220 hospitalized patients treated with micafungin or other parenteral antifungals.
Schneeweiss S; Carver PL; Datta K; Galar A; Johnson MD; Letourneau AR; Marty FM; Nagel J; Najdzinowicz M; Saul M; Schuster M; Shoham S; Silveira FP; Varughese C; Wilck M; Weatherby L; Oene JV; Walker AM
J Antimicrob Chemother; 2020 Jan; 75(1):221-228. PubMed ID: 31580432
[TBL] [Abstract][Full Text] [Related]
3. Safety of high-dose micafungin for patients with hematological diseases.
Yamazaki S; Nakamura F; Yoshimi A; Ichikawa M; Nannya Y; Kurokawa M
Leuk Lymphoma; 2014 Nov; 55(11):2572-6. PubMed ID: 24460099
[TBL] [Abstract][Full Text] [Related]
4. Micafungin versus amphotericin B lipid complex for the prevention of invasive fungal infections in high-risk liver transplant recipients.
Sun HY; Cacciarelli TV; Singh N
Transplantation; 2013 Sep; 96(6):573-8. PubMed ID: 23842191
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Intermittent Intravenous Administration of High-Dose Micafungin.
Neofytos D; Huang YT; Cheng K; Cohen N; Perales MA; Barker J; Giralt S; Jakubowski A; Papanicolaou G
Clin Infect Dis; 2015 Dec; 61 Suppl 6(Suppl 6):S652-61. PubMed ID: 26567284
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
[TBL] [Abstract][Full Text] [Related]
7. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study.
Mehta PA; Vinks AA; Filipovich A; Bleesing J; Jodele S; Jordan MB; Marsh R; Tarin R; Edwards S; Fearing D; Lawrence J; Davies SM
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1458-62. PubMed ID: 20546908
[TBL] [Abstract][Full Text] [Related]
8. [Differential pharmacokinetic characteristics of micafungin. Experience in special populations].
Grau Cerrato S; Luque Pardos S; Ferrández Quirante O
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():10-4. PubMed ID: 21420571
[TBL] [Abstract][Full Text] [Related]
9. Caspofungin versus micafungin in the incidence of hepatotoxicity in patients with normal to moderate liver failure.
Shibata Y; Hagihara M; Kato H; Kawasumi N; Hirai J; Nishiyama N; Asai N; Koizumi Y; Yamagishi Y; Matsuura K; Mikamo H
J Infect Chemother; 2017 Jun; 23(6):349-353. PubMed ID: 28431933
[TBL] [Abstract][Full Text] [Related]
10. Comparison of micafungin and voriconazole in the treatment of invasive fungal infections in kidney transplant recipients.
Shang W; Feng G; Sun R; Wang X; Liu W; Zhang S; Li J; Pang X; Wang Y; Zhang W
J Clin Pharm Ther; 2012 Dec; 37(6):652-6. PubMed ID: 22725946
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis associated with micafungin use in a preterm infant.
King KY; Edwards MS; Word BM
J Perinatol; 2009 Apr; 29(4):320-2. PubMed ID: 19325554
[TBL] [Abstract][Full Text] [Related]
12. [Is micafungin useful in the prophylaxis of invasive fungal disease in hematological patients?].
Salavert M; Jarque I
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 2():43-9. PubMed ID: 21420577
[TBL] [Abstract][Full Text] [Related]
13. Micafungin for empirical antifungal therapy in patients with febrile neutropenia: multicenter phase 2 study.
Mizuno H; Sawa M; Yanada M; Shirahata M; Watanabe M; Kato T; Nagai H; Ozawa Y; Morishita T; Tsuzuki M; Goto E; Tsujimura A; Suzuki R; Atsuta Y; Emi N; Naoe T
Int J Hematol; 2013 Aug; 98(2):231-6. PubMed ID: 23857638
[TBL] [Abstract][Full Text] [Related]
14. Safety of micafungin in pediatric clinical trials.
Arrieta AC; Maddison P; Groll AH
Pediatr Infect Dis J; 2011 Jun; 30(6):e97-e102. PubMed ID: 21378595
[TBL] [Abstract][Full Text] [Related]
15. Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases.
Cornely OA; Pappas PG; Young JA; Maddison P; Ullmann AJ
Expert Opin Drug Saf; 2011 Mar; 10(2):171-83. PubMed ID: 21306282
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients.
Saliba F; Pascher A; Cointault O; Laterre PF; Cervera C; De Waele JJ; Cillo U; Langer RM; Lugano M; Göran-Ericzon B; Phillips S; Tweddle L; Karas A; Brown M; Fischer L; ;
Clin Infect Dis; 2015 Apr; 60(7):997-1006. PubMed ID: 25520332
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of micafungin as an empirical therapy for invasive fungal infections in patients with hematologic disorders: a multicenter, prospective study.
Yamaguchi M; Kurokawa T; Ishiyama K; Aoki G; Ueda M; Matano S; Takami A; Yamazaki H; Sawazaki A; Yamauchi H; Yoshida T; Nakao S
Ann Hematol; 2011 Oct; 90(10):1209-17. PubMed ID: 21695388
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders.
Tamura K; Urabe A; Yoshida M; Kanamaru A; Kodera Y; Okamoto S; Maesaki S; Masaoka T
Leuk Lymphoma; 2009 Jan; 50(1):92-100. PubMed ID: 19172498
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of micafungin as an empirical antifungal agent for febrile neutropenic patients with hematological diseases.
Park JS; Kim DH; Choi CW; Jeong SH; Choi JH; Kim K; Kim SJ; Jung CW; Yang DH; Jang JH
Acta Haematol; 2010; 124(2):92-7. PubMed ID: 20664196
[TBL] [Abstract][Full Text] [Related]
20. Micafungin twice weekly as antifungal prophylaxis in paediatric patients at high risk for invasive fungal disease.
Bochennek K; Balan A; Müller-Scholden L; Becker M; Farowski F; Müller C; Groll AH; Lehrnbecher T
J Antimicrob Chemother; 2015 May; 70(5):1527-30. PubMed ID: 25564562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
